Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes -

6 hours ago

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease linked to obesity and metabolic dysfunction.
Incretin-based therapies, including GLP-1 RAs and dual GIP/GLP-1 receptor agonists, are being explored for HS management.
Studies show incretin-based therapies lead to weight loss and improvements in HS disease activity, flare frequency, pain, and quality of life.
Improvements in HS outcomes are generally associated with weight reduction, suggesting metabolic effects play a primary role.
Evidence for weight-independent anti-inflammatory effects of incretin-based therapies in HS is limited and inconclusive.
Incretin-based therapies may benefit HS patients with obesity or metabolic syndrome, but current data are observational.
Prospective controlled studies are needed to clarify mechanisms and define the role of incretin-based therapies in HS management.

Hasty Briefsbeta